RxDoctor Payments Data

Sarah Nehls, MD

Ophthalmology · Madison, WINPI 1841266368

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 87.9% of it on its own, with 2 other manufacturers making up the rest.

$871in general payments, 2019–2025

Across 12 payments — averaging $72.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$765
  • Bausch & Lomb Americas Inc.$78
  • Johnson & Johnson Surgical Vision, Inc.$28
$11,447in research payments, 2019–2025

Across 6 payments — averaging $1907.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shire North American Group Inc$11K
  • Takeda Pharmaceuticals U.S.A., Inc.$900

What the payments were for

  • Food & beverage$871100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$871 in reported general payments places this provider in the 65th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$246,971
Medicare patients
551
Services billed
1,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast32$29,155
Cyclosporine63$23,602
RestasisCyclosporine26$22,759
DurezolDifluprednate19$16,234
NatacynNatamycin17$15,014
Prednisolone Acetate278$11,858
LumiganBimatoprost11$7,986
Fluorometholone83$6,551
Loteprednol Etabonate35$6,023
Brimonidine Tartrate29$3,765
Ketorolac Tromethamine204$3,282
ValacyclovirValacyclovir Hcl60$2,532
Dorzolamide-TimololDorzolamide/Timolol/Pf11$2,365
MoxifloxacinMoxifloxacin Hcl116$2,051
Difluprednate16$1,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$78$29,15532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →